Company
Hemogenyx Pharmaceuticals PLC
LON:HEMO
Hemogenyx Pharmaceuticals PLC is a clinical-stage biopharmaceutical group developing new medicines and treatments for life-threatening diseases. Hemogenyx Pharmaceuticals is developing several distinct and complementary product candidates, as well as a platform technology that it uses as an engine for novel product development.
128 stories · page 2 of 7
Investments and investor services
Hemogenyx Pharmaceuticals making pleasing progress
"The board is very pleased with the progress being made with the unlocking of additional opportunities for the CDX antibodies, as well as the potential value that can be created through the company's updated humanised mouse model,” said cha
Hemogenyx Pharmaceuticals PLC advisory board member recognised for breast cancer breakthrough
H. Michael Shepard’s ground-breaking work on the discovery of Herceptin, the now widely-prescribed breast cancer drug, has been acknowledged with the 2019 Lasker-DeBakey Clinical Medical Research Award
Archive
Proactive news snapshot: Faron Pharmaceuticals, Pan African Resources, Iofina, Open Orphan …
A glance at some of the day's highlights from the Proactive Investors newswire
Hemogenyx files new patent application for CDX technology
The application covers the antibody's use in conditioning patients for bone marrow transplant and its deployment in a number of hard-to-treat blood borne diseases, including acute myeloid leukaemia
Investments and investor services
FTSE 100 closes lower Friday after lacklustre week
The FTSE 250 went the other way and gained over 87 points on Friday
Investments and investor services
FTSE 100 closes higher on day and week as world leaders meet
The mid-cap FTSE 250 added over 147 points to close at 19,462 on Friday
Archive
City’s eyes turn to G20 summit on quiet Friday in London
With little company news due on Friday, investors will instead be looking to the latest G20 summit in Osaka, Japan
Archive
Proactive news snapshot: Kibo Energy, CentralNic, OptiBiotix Health...
A glance at some of the day's highlights from the Proactive Investors newswire